These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2095926)

  • 21. Tamoxifen, serum lipoproteins and cardiovascular risk.
    Bruning PF; Bonfrer JM; Hart AA; de Jong-Bakker M; Linders D; van Loon J; Nooyen WJ
    Br J Cancer; 1988 Oct; 58(4):497-9. PubMed ID: 3207604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.
    Love RR; Wiebe DA; Newcomb PA; Cameron L; Leventhal H; Jordan VC; Feyzi J; DeMets DL
    Ann Intern Med; 1991 Dec; 115(11):860-4. PubMed ID: 1952472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina.
    Bradbury BD; Lash TL; Kaye JA; Jick SS
    Cancer; 2005 Mar; 103(6):1114-21. PubMed ID: 15712362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
    Ntukidem NI; Nguyen AT; Stearns V; Rehman M; Schott A; Skaar T; Jin Y; Blanche P; Li L; Lemler S; Hayden J; Krauss RM; Desta Z; Flockhart DA; Hayes DF;
    Clin Pharmacol Ther; 2008 May; 83(5):702-10. PubMed ID: 17713466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.
    Love RR; Wiebe DA; Feyzi JM; Newcomb PA; Chappell RJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1534-9. PubMed ID: 7932809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy.
    Yeo W; Mo FKF; Pang E; Suen JJS; Koh J; Loong HHF; Yip CCH; Ng RYW; Yip CHW; Tang NLS; Liem GS
    BMC Womens Health; 2017 Jul; 17(1):55. PubMed ID: 28750616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
    Wasan KM; Goss PE; Pritchard PH; Shepherd L; Tu D; Ingle JN
    Breast Cancer Res Treat; 2012 Dec; 136(3):769-76. PubMed ID: 23089983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
    Lewis S
    Am Heart J; 2007 Feb; 153(2):182-8. PubMed ID: 17239675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    Hong N; Yoon HG; Seo DH; Park S; Kim SI; Sohn JH; Rhee Y
    Eur J Cancer; 2017 Sep; 82():103-114. PubMed ID: 28651157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
    Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Could Anthropometric and Lipid Parameters Reflect Susceptibility to Breast Cancer? Comparison of Newly Diagnosed Breast Cancer and Apparently Healthy Women.
    Akalanka HMK; Ekanayake S; Samarasinghe K
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2475-2480. PubMed ID: 30255702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 codon 655 G-allele is associated with reductions in plasma high-density lipoprotein levels in breast cancer patients treated with tamoxifen.
    Chang NW; Chen DR; Chen FN; Lin C; Wu CT
    J Investig Med; 2011 Dec; 59(8):1252-7. PubMed ID: 21997313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.
    Love RR; Newcomb PA; Wiebe DA; Surawicz TS; Jordan VC; Carbone PP; DeMets DL
    J Natl Cancer Inst; 1990 Aug; 82(16):1327-32. PubMed ID: 2199681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy.
    Kim JY; Cho N; Jeyanth JX; Kim WH; Lee SH; Gweon HM; Moon WK
    AJR Am J Roentgenol; 2014 Apr; 202(4):912-21. PubMed ID: 24660724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer.
    Ong PJ; Linardou H; Graham HA; Savage P; Hayward CS; Coombes RC; Collins P
    Am Heart J; 2001 Oct; 142(4):E6. PubMed ID: 11579370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.
    Rutqvist LE; Mattsson A
    J Natl Cancer Inst; 1993 Sep; 85(17):1398-406. PubMed ID: 8350363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tamoxifen therapy in breast cancer: do apolipoprotein E genotype and menopausal state affect plasma lipid changes induced by the drug?
    Gaibar M; Fernández G; Romero-Lorca A; Novillo A; Tejerina A; Bandrés F; Fernández-Santander A
    Int J Biol Markers; 2013 Dec; 28(4):e371-6. PubMed ID: 23828408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.